14.35 USD
▲+0.04+5.98%
盘后 13.80 +1.92%
2026-08-03
市值
$210.63M
市盈率
—
EPS
-1.60
股息率
—
52 周区间
7.78 – 34.10
成交量
151.04K
Beta
1.39
目标价
57.00
52W 低 7.7852W 高 34.10
价格走势
公司简介
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSc...